Immuron Says Study Shows Benefits of IMM-124E Health Supplement


By Chris Wack


Immuron Ltd. said a recent publication reported on the potential antiviral benefits of IMM-124E in a mouse model and a human clinical study.

The biopharmaceutical company said that its proprietary product IMM-124E is used to make its commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn.

The studies used in the journal Drug Development Research were conducted independently by the Hadassah Medical Center in Jerusalem.

The aim of the research study was to determine the ability of IMM-124E to promote antiviral T-cell responses to interferon, the company said.

In the preclinical study, mice were administered orally with HBC for five days and tested for the number of T cell clones in response to viral antigens of swine flu, New Caledonian influenza, and cytomegalovirus. . The reported data suggests that IMM-124E improved antiviral immunity among the viral strains tested, the company said.

A similar response was observed in the human study. Preliminary reported clinical data suggests that a similar effect has been observed in humans by increasing antiviral responses against Covid-19 and hepatitis B, the company said.

The company said it has filed for a patent cooperation treaty seeking international patent protection for IMM-124E, which has demonstrated neutralizing activity against severe acute respiratory syndrome coronavirus-2 , the virus that causes Covid-19.

Immuron shares rose 17% to $ 4.14 in pre-market trading.


Write to Chris Wack at [email protected]

Previous Immutep Limited (ASX: IMM): Are analysts optimistic?
Next Immuron: IMM124E - Demonstrates antiviral immunity against T cells - Form 6-K